Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-SCT15 FLAMEL conditioning study for pediatric AML
jRCTs051180190Phase 2Active, not recruiting
- Start
- Sep 2017
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludarabine, cytarabine, melphalan, tacrolimus, cyclosporine and 1 more in acute myeloid leukemia (AML) (2 arms). Primary endpoint: Overall survival at 3 years after transplantation. Started Sep 2017; status: active, not recruiting.
02
Drugs
fludarabinecytarabinemelphalantacrolimuscyclosporine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCTs051180190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180190.